Comparison of SB17 and reference ustekinumab in healthy adults: A  randomized, double-blind, single-dose, phase I study

CONCLUSION: This study demonstrated bioequivalence of SB17, EU-UST, and US-UST in terms of PK. Safety, tolerability, and immunogenicity were also comparable between all groups.PMID:38174886 | DOI:10.5414/CP204492

Source: International Journal of Clinical Pharmacology and Therapeutics - January 4, 2024 Category: Drugs & Pharmacology Authors: Hansol Jeong Taeseung Kang Jiyoon Lee Seongsik Im Source Type: research